TB Host Directed Therapy

Tuberculosis Clinical Trial

— TBHDT  

Official title:

A Ph2 Randomized Trial to Evaluate the Safety Preliminary Efficacy and Biomarker Response of Host Directed Therapies Added to Rifabutin-modified Standard Therapy in Adults With Drug-Sensitive Smear-Positive Pulmonary TB

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02968927
• Other study ID #: TBHDT-AUR1-8-178
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: November 2016
• Est. completion date: December 2020

Study information

• Verified date: January 2019
• Source: The Aurum Institute NPC
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To examine the safety and preliminary efficacy of multiple adjunctive host directed TB therapies (TB HDT), to assess their potential to shorten TB treatment and/or prevent permanent lung damage.

Description:

OBJECTIVES:

To determine the safety and preliminary efficacy of 4 TB HDT candidates:

1. Safety (treatment emergent serious adverse events and SUSARs)

2. Microbiologic effects in sputum (culture conversion, change in MGIT TTP) and blood (WBA)

3. PET/CT imaging

4. Serum markers of inflammation

5. Effects on Mtb-specific and general immune function

6. Pulmonary effects (spirometry, 6MWT, O2 saturation, and St. George Respiratory Symptom Questionnaire) In each case, TB HDT effects will be determined by comparison to patients treated with standard TB therapy alone with regard to a common set of primary and secondary endpoints.

PRIMARY ENDPOINTS

1. For auranofin, everolimus, and vitamin D: the proportions of patients experiencing suspected unexpected serious adverse reactions (SUSARs).

2. For CC-11050: the proportion of patients experiencing treatment emergent serious adverse events (SAEs).

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 200
• Est. completion date: December 2020
• Est. primary completion date: September 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Willing and able to provide signed written consent or witnessed oral consent in the case of illiteracy, prior to undertaking any trial-related procedures.

2. Aged 18 to 65 years, male, or if female, either not of reproductive potential (post-menopause, or status-post surgical sterilization) or with an intrauterine contraceptive device in place.

3. Body weight (in light clothing without shoes) between 40 and 90 kg.

4. First episode of pulmonary tuberculosis diagnosed by positive sputum AFB smear with subsequent culture confirmation OR positive Xpert TB/RIF with Ct <20 [4].

5. RIF susceptibility diagnosed by Xpert TB/RIF OR Hain test

6. Chest radiograph meeting criteria for moderate or far advanced pulmonary tuberculosis [5]

7. HIV-1 seronegative

8. HBsAg negative

Exclusion Criteria:

1. Any condition for which participation in the trial, as judged by the investigator, could compromise the well-being of the subject or prevent, limit or confound protocol specified assessments

2. Current or imminent treatment for malaria.

3. Is critically ill, and in the judgment of the investigator has a diagnosis likely to result in death during the trial or the follow-up period.

4. TB meningitis or other forms of severe tuberculosis with high risk of a poor outcome as judged by the investigator.

5. History of allergy or hypersensitivity to any of the trial therapies or related substances, including known allergy or suspected hypersensitivity to rifampin or rifabutin.

6. Having participated in other clinical trials with investigational agents within 8 weeks prior to trial start or currently enrolled in an investigational trial.

7. Subjects with any of the following at screening:

1. Cardiac arrhythmia requiring medication;

2. Prolongation of QT/QTc interval with QTcF (Fridericia correction) >450 ms;

3. History of additional risk factors for Torsade de Pointes, (e.g., heart failure, hypokalemia, family history of Long QT Syndrome);

4. Any clinically significant ECG abnormality, in the opinion of the investigator.

5. Patients requiring concomitant medications that prolong the QT inter-val.

8. Random blood glucose >140 mg/dL, or history of unstable Diabetes Mellitus which required hospitalization for hyper- or hypoglycaemia within the past year prior to start of screening.

9. Use of systemic corticosteroids within the past 28 days.

10. Subjects with any of the following abnormal laboratory values:

1. creatinine >2 mg/dL

2. haemoglobin <8 g/dL

3. platelets <100x109 cells/L

4. serum potassium <3.5

5. aspartate aminotransferase (AST) =2.0 x ULN

6. alkaline phosphatase (AP) >5.0 x ULN

7. total bilirubin >1.5 mg/dL

Related Conditions & MeSH terms

• Tuberculosis

Intervention

Drug:
• Everolimus 0.5 MG

• Auranofin 6 MG

• Vitamin D3

• CC-11050

• 2HRbZE/4HRb

Locations

Country	Name	City	State
South Africa	The Aurum Institute: Tembisa Clinical Research Centre	Tembisa	Gauteng

Sponsors (1)

Lead Sponsor	Collaborator
The Aurum Institute NPC

Country where clinical trial is conducted

South Africa, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Change in FEV1 from baseline to 2 and 6 months	FEV1 (% of expected value)	days 56 and 180
Other	18F-FDG PET/CT imaging (change from baseline to 2 months):	Maximum and mean standardized uptake values (SUV)	day 56
Other	Serum neopterin	change from baseline b. CRP	day 56
Other	Quantiferon gold in tube	change from baseline	day 56
Other	Gene expression profiles (exploratory)	Change from baseline to 2 and 6 months in gene expression profiles	days 56 and 180
Other	PD-1 expression (exploratory)	PD-1 expression on CD4 and CD8 lymphocytes	days 56 and 180
Primary	SAEs and SUSARs	For auranofin, everolimus, and vitamin D: the proportions of patients experiencing suspected unexpected serious adverse reactions (SUSARs).; For CC-11050: the proportion of patients experiencing treatment emergent serious adverse events (SAEs).	through day 180
Secondary	TEAEs other than SAEs and SUSARs	TEAEs other than SAEs, categorized according to severity, drug relatedness, and leading to early withdrawal.	through day 180
Secondary	Sputum culture status on day 56	Proportion of patients with positive sputum cultures on solid culture medium after 8 weeks of treatment	day 56